REGENERON PHARMACEUTICALS, INC. Prepaid Expense and Other Assets, Current
REGENERON PHARMACEUTICALS, INC. (REGN) had Prepaid Expense and Other Assets, Current of $801.70 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-07-30
- 2026-06-30: Prepaid Expense and Other Assets, Current $801.70M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $620.90M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $474.80M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $595.60M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $801.70M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $620.90M 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $474.80M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $595.60M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $574.30M 10-Q · filed 2025-08-01 | |
| 2025-03-31 | $468.90M 10-Q · filed 2025-04-29 | |
| 2024-12-31 | $349.20M 10-K · filed 2026-02-04 | |
| 2024-09-30 | $412.00M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $681.90M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $414.90M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $386.60M 10-K · filed 2025-02-05 | |
| 2023-09-30 | $574.70M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $366.30M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $406.20M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $411.20M 10-K · filed 2024-02-05 | |
| 2022-09-30 | $446.40M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $583.60M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $424.90M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $332.40M 10-K · filed 2023-02-06 | |
| 2021-09-30 | $482.00M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $444.30M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $213.60M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $160.80M 10-K · filed 2022-02-07 | |
| 2020-09-30 | $230.60M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $263.80M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $226.60M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $273.70M 10-K · filed 2021-02-08 | $387.10M 10-K · filed 2020-02-07 |
| 2019-09-30 | $226.90M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $208.20M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $182.20M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $243.30M 10-K · filed 2020-02-07 | |
| 2018-09-30 | $284.81M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $163.60M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $155.45M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $225.10M 10-K · filed 2019-02-07 | $224.97M 10-K · filed 2018-02-08 |
| 2017-09-30 | $143.76M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $193.33M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $146.06M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $130.53M 10-K · filed 2018-02-08 | |
| 2016-09-30 | $103.81M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $96.02M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $115.69M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $163.50M 10-K · filed 2017-02-09 | |
| 2015-09-30 | $89.49M 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $43.10M 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $34.10M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $79.05M 10-K · filed 2016-02-11 | $71.49M 10-K · filed 2015-02-12 |
| 2014-09-30 | $61.73M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $60.67M 10-Q · filed 2014-08-05 | |
| 2014-03-31 | $52.25M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $32.95M 10-K · filed 2015-02-12 | $96.14M 10-K · filed 2014-02-13 |
| 2013-09-30 | $156.84M 10-Q · filed 2013-11-05 | |
| 2013-06-30 | $108.91M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $97.14M 10-Q · filed 2013-05-03 | |
| 2012-12-31 | $28.02M 10-K · filed 2014-02-13 | $56.66M 10-K · filed 2013-02-15 |
| 2012-09-30 | $84.78M 10-Q · filed 2012-10-24 | |
| 2012-06-30 | $32.79M 10-Q · filed 2012-07-25 | |
| 2012-03-31 | $26.27M 10-Q · filed 2012-04-26 | |
| 2011-12-31 | $35.80M 10-K · filed 2013-02-15 | $22.90M 10-K · filed 2012-02-21 |
| 2011-09-30 | $15.93M 10-Q · filed 2011-10-27 | |
| 2011-06-30 | $19.03M 10-Q · filed 2011-07-28 | |
| 2010-12-31 | $26.34M 10-K · filed 2012-02-21 | $15.14M 10-Q · filed 2011-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |